QS-21
drugOn this page
Also known as Purified quillaja saponinQs 21Qs-21 adjuvantQs-21 component of alfq qs21Qs-21 component of as01Qs-21 component of as01eQS21Quillaja saponin (qs-21)SAPONIN QA-21V1Stimulon
Summary
Qs-21 (CHEMBL4297817) is a phase-3 clinical-stage unknown; indicated across 15 conditions including cutaneous melanoma and leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 15 conditions
- Clinical trials: 30
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297817 |
| Name | QS-21 |
| Type | Unknown |
| Max phase | 3 |
Also known as: Purified quillaja saponin, Qs 21, Qs-21, Qs-21 adjuvant, Qs-21 component of alfq qs21, Qs-21 component of as01, Qs-21 component of as01e, QS21, Quillaja saponin (qs-21), SAPONIN QA-21V1, Stimulon, QS-21
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
15 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| prostate carcinoma | 2 | MONDO:0005159 | EFO:0001663 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| herpes simplex infectious disease | 2 | MONDO:0004609 | EFO:1002022 |
| Alzheimer disease | 2 | MONDO:0004975 | MONDO:0004975 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| peritoneal neoplasm | 1 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 1 | MONDO:0021092 | MONDO:0002158 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| follicular lymphoma | 1 | MONDO:0018906 | MONDO:0018906 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 30.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 15 |
| PHASE2 | 12 |
| Not specified | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00005052 | PHASE3 | UNKNOWN | Vaccine Therapy in Treating Patients With Primary Stage II Melanoma |
| NCT05638698 | PHASE2 | ACTIVE_NOT_RECRUITING | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer |
| NCT00003362 | PHASE2 | COMPLETED | Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma |
| NCT00004052 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia |
| NCT00004249 | PHASE2 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy |
| NCT00479557 | PHASE2 | COMPLETED | Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer’s Disease |
| NCT00498602 | PHASE2 | COMPLETED | Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer’s Disease |
| NCT00579423 | PHASE2 | COMPLETED | Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer |
| NCT00752232 | PHASE2 | COMPLETED | Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer’s Disease |
| NCT00955409 | PHASE2 | COMPLETED | Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer’s Disease |
| NCT00959192 | PHASE2 | COMPLETED | Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer’s Disease |
| NCT00960531 | PHASE2 | TERMINATED | A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer’s Disease |
| NCT01687595 | PHASE2 | COMPLETED | Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes |
| NCT00000809 | PHASE1 | WITHDRAWN | Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women |
| NCT00001044 | PHASE1 | COMPLETED | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults. |
| NCT00001052 | PHASE1 | COMPLETED | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults |
| NCT00001096 | PHASE1 | COMPLETED | A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults |
| NCT00001572 | PHASE1 | COMPLETED | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype |
| NCT00003224 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| NCT00003357 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease |
| NCT00003819 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer |
| NCT00004156 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Breast Cancer |
| NCT00004929 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer |
| NCT00005632 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer |
| NCT00006041 | PHASE1 | COMPLETED | Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
| NCT00006387 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer |
| NCT00036933 | PHASE1 | COMPLETED | Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer |
| NCT06741072 | PHASE1 | SUSPENDED | BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants |
| NCT00030823 | Not specified | COMPLETED | Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence |
| NCT00470574 | Not specified | COMPLETED | Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: cutaneous melanoma